ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announce
(Financial Post, 2025-11-03T21:07:47Z)